News

A move to cover expensive weight-loss drugs for Americans on Medicare and Medicaid may be in the works, but any such program ...
The number of U.S. adults that are aware of GLP-1 drugs used for weight loss, such as Ozempic and Wegovy, has jumped ...
The federal government is expected to start a 5-year-long experiment that will provide some limited coverage of obesity ...
Blockbuster weight loss drugs like Wegovy and Zepbound have surged in popularity, but high prices have left them out of reach for many obese Americans.
Ozempic (semaglutide) and other GLP-1 medications have helped many people lose weight and manage chronic conditions like type ...
A five-year experiment aims to open access to blockbuster GLP‑1 drugs for obesity, something advocates have pushed for years.
Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...
The Trump administration is planning an experiment to cover weight loss drugs under Medicare and Medicaid, potentially ...
Several anti-obesity drugs, including Ozempic, Wegovy and Mounjaro, have created buzz in the Indian markets. But are they really approved for use in India? What are their side-effects? And how much do ...
President Donald Trump's new European tariffs may spell bad news for Novo Nordisk, maker of Ozempic and Wegovy. As Axios ...
Drugs known as GLP-1 receptor agonists were initially developed to treat Type 2 diabetes but have become a cultural phenomenon.
Investors and analysts say they expect Eli Lilly to report stronger quarterly sales and profit next week than Danish rival ...